A Brief History of the Development of Diabetes Medications
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In Brief This article provides an overview of the development of insulins, oral agents, and noninsulin injectable agents used in the management of hyperglycemia in patients with diabetes. It also briefly reviews the pharmacological impact and salient side effects of these medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects
Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S., & Habener, J. F. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.270 · Cited by 289
Research works printed but not linked: 14
- Sanders, 2002, From Thebes to Toronto and the 21st century: an incredible journey, Diabetes Spectrum, 15, 56, 10.2337/diaspect.15.1.56 · doi:10.2337/diaspect.15.1.56
- Galloway, 1988, Diabetes Mellitus
- Daneman, 1981, Progressive retinopathy with improved control in diabetic dwarfism (Mauriac's syndrome), Diabetes Care, 4, 360, 10.2337/diacare.4.3.360 · DOI · Paper page
- White, 2008, Overview of the medications used to treat type 2 diabetes, 5
- Frank, 1926, Über synthetische dargestellte Korper mit Insulinartiger Wirkung auf den normallen und diabetisched Organismus, Klin Wchnschr, 5, 2011, 10.1007/BF01736560 · DOI
- Alberti, 1997, International Textbook of Diabetes Mellitus
- Levine, 1984, Sulfonylureas: background and development of the field, Diabetes Care, 7, 3
- Quianzon, 2012, History of current non-insulin medications for diabetes mellitus, J Community Hosp Intern Med Perspect., 10.3402/jchimp.v2i3.19081 · DOI
- Kendall, 2006, Thiazolidinediones: the case for early use, Diabetes Care, 29, 154, 10.2337/diacare.29.01.06.dc05-0711 · DOI · Paper page
- Aroda, 2011, The safety and tolerability of GLP-1 receptor agonist in the treatment of type 2 diabetes: a review, Diabetes Metab Res Rev, 27, 528, 10.1002/dmrr.1202 · DOI · Paper page
- Neumiller, 2009, Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonist and DPP-4 inhibitors, J Am Pharm Assoc, 49, S14
- White, 2010, Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT-2 inhibition, Clinical Diabetes, 28, 5, 10.2337/diaclin.28.1.5 · DOI
- Monami, 2013, Efficacy and safety of sodium glucose cotransport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials, Diabetes Obes Metab.
- Goodkin, 1975, Mortality factors in diabetes: a 20 year mortality study [Abstract], J Occup Med, 17, 716
Cited by
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., et al. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_556_17 · Cited by 101
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., Azoulay, L., & Patorno, E. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15196 · Cited by 39
Durden, E., Liang, M., Fowler, R., Panton, U. H., & Mocevic, E. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.18429 · Cited by 30
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
“Even if the “incretin effect” is a long-known concept (White, 2014), the first GLP-1 RA, exenatide, was approved by the European Medicine Agency (EMA) only in 2006, followed by liraglutide (2009), lixisenatide (2013), dulaglutide (2014), semaglutide (2018), and the dual GIP and GLP-1 receptor…”
Metadata
- Authors
- White, J. R.
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2014-05-01
- Volume
- 27
- Issue
- 2
- Pages
- 82-86
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- OpenAlex
- W2041652400
- Cited by
- 177
- References
- 4
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.